Share this article
Share this article
LONDON, Feb. 17, 2021 /PRNewswire/ Theragnostics, which is developing molecular radiotherapy for imaging and treating a broad range of cancers, today announces a research collaboration with Essen University Hospital to examine Theragnostics investigational agent THG-008 for PET imaging in a range of cancers.
The research is due to start in February 2021 and will be led by Dr. Michael Nader, head of radiochemistry and part of the Clinic for Nuclear Medicine at Universitätsklinikum Essen (University Hospital Essen), in Germany.
THG-008 is a novel fluorine-18 radiolabelled PARP inhibitor (
18F-PARPi) which has a number of applications relevant to imaging cancer. A Phase 1 clinical study for THG-008 in head and neck squamous cell carcinoma (HNSCC) completed recruitment in May 2019. Data published in a peer-reviewed publication confirmed imaging of head and neck cancer with
Loading video.
VIDEO: Alexander Stremitzer discusses the legal implications for physicians of following artificial intelligence advice in this new video from The Journal of Nuclear Medicine. view more
Credit: Video created by Alexander Stremitzer and Eidgenössische Technische Hochschule Zürich Center for Law and Economics.
Reston, Virginia Physicians who follow artificial intelligence (AI) advice may be considered less liable for medical malpractice than is commonly thought, according to a new study of potential jury candidates in the U.S. Published in the January issue of
The Journal of Nuclear Medicine (JNM). The study provides the first data related to physicians potential liability for using AI in personalized medicine, which can often deviate from standard care.
Credit: Society of Nuclear Medicine and Molecular Imaging.
Reston, Virginia The
Journal of Nuclear Medicine (JNM) has issued a special supplement commemorating six decades of leadership in the field of nuclear medicine, molecular imaging and therapy.
The supplement features a collection of the most influential and frequently cited manuscripts in JNM s history, representing seminal discoveries and scientific contributions that shaped the future of medicine. Invited perspectives from world leaders in nuclear medicine, molecular imaging, and theranostics explain why each of these articles had such an enormous impact.
Highlights include milestone articles on the invention of the Anger camera, the creation of positron emission tomography (PET) and 18F-FDG, the development of fusion PET/CT, the introduction of FDG PET-based response criteria in solid tumors, and many more landmark papers that have shaped the history of nuclear medicine.